Erbitux might help lung cancer fight
A cancer drug used to treat colon, head and neck cancer is said to boost survival rates in patients with certain type of lung cancer. Janet Babin reports dramatic Erbitux trial results could make prescriptions explode.
A pharmacist counts pills to fill a prescription. (Joe Raedle/Getty Images)
More on Health
TEXT OF STORY
Renita Jablonski: The most important meeting of the year for cancer researchers opens today in Chicago. There's particular interest in a new medication for lung cancer. Janet Babin reports from the Marketplace Innovations Desk at North Carolina Public Radio.
Janet Babin: The new drug is called Erbitux, made by biotech company ImClone. It's already used to treat colon, head and neck cancer.
The company says Erbitux can also boost survival in patients with certain types of lung cancer. It'll release key trial results this weekend at the American Society of Clinical Oncology meeting.
Wachovia analyst George Farmer is eager to see the details:
George Farmer: Everyone is looking at this data very keenly to see the benefit that Erbitux could provide. This could have great impact on how drugs like Erbitux are used in treating front-line lung cancer.
If the trial results are dramatic, prescriptions for Erbitux could explode. That would benefit ImClone and its partner, Bristol-Myers.
But it could hurt Genentech. It makes Avastin, a different type of lung cancer drug.
Lung cancer is the leading cause of cancer deaths in the U.S., and costs billions of dollars each year to treat.
I'm Janet Babin for Marketplace.
Comments
Comment | Refresh
Post a Comment: Please be civil, brief and relevant.
Email addresses are never displayed, but they are required to confirm your comments. All comments are moderated. Marketplace reserves the right to edit any comments on this site and to read them on the air if they are extra-interesting. Please read the Comment Guidelines before posting.
You must be 13 or over to submit information to American Public Media. The information entered into this form will not be used to send unsolicited email and will not be sold to a third party. For more information see Terms and Conditions and Privacy Policy.